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Background: Current literature provides limited data on the hemodynamic changes that may occur during bi-level
continuous positive airway pressure (CPAP) support in preterm infants. However, the application of a positive
end-expiratory pressure may be transmitted to the heart and the great vessels resulting in changes of central
blood flow.
Objective: To assess changes in central blood flow in infants with respiratory distress syndrome (RDS) during
bi-level CPAP support.
Design: A prospective study was performed in a cohort of 18 Very-Low-Birth-Weight Infants who were put on nasal
CPAP support (4–5 cmH2O) because they developed RDS within the first 24–72 hours of life. Each subject was
switched to bi-level CPAP support (Phigh 8 cmH2O, Plow 4–5 cmH2O, Thigh 0.5-0.6 seconds, 20 breaths/min) for an
hour. An echocardiographic study and a capillary gas analysis were performed before and after the change of
respiratory support.
Results: No differences between n-CPAP and bi-level CPAP in left ventricular output (LVO, 222.17 ± 81.4 vs
211.4 ± 75.3 ml/kg/min), right ventricular output (RVO, 287.8 ± 96 vs 283.4 ± 87.4 ml/kg/min) and superior vena
cava flow (SVC, 135.38 ± 47.8 vs 137.48 ± 46.6 ml/kg/min) were observed. The hemodynamic characteristics of
the ductus arteriosus were similar. A significant decrease in pCO2 levels after bi-level CPAP ventilation was
observed; pCO2 variations did not correlate with modifications of central blood flow (LVO: ρ = 0.11, p = 0,657;
RVO: ρ = −0.307, p = 0.216; SVC: ρ = −0.13, p = 0.197).
Conclusions: Central blood flow doesn’t change during bi-level CPAP support, which could become a hemodinamically
safe tool for the treatment of RDS in preterm infants.Introduction
Bi-level CPAP is a form of respiratory support routinely
used to assist adults and children. It enables the patient
to breathe spontaneously between two different levels of
continuous positive pressure, the upper (IPAP) and the
lower level (EPAP). The cycle time can be either selected
by the operator or synchronized with the patient’s
respiratory effort. Both IPAP and EPAP are generated by
an increase in the gas flow through the circuit without
closing the expiratory valve enabling the patient to exhale
anytime, even during the IPAP phase [1]. The aim of* Correspondence: silvia.galletti4@unibo.it
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unless otherwise stated.bi-level CPAP is to improve alveolar recruitment, gas
exchange and, by a direct stimulation of the upper airways,
to prevent apneas requiring intubation.
Nasal CPAP (n-CPAP) is currently considered the treat-
ment of choice for neonatal respiratory distress syndrome
(RDS) [2]. By applying a constant distending pressure to
the airways n-CPAP maintains the functional residual
capacity (FRC) of the lungs through alveolar recruitment
and stabilization. This constant pressure prevents alveolar
collapse during expiration, improves gas exchange and
reduces the work of breathing facilitating the next in-
spiratory phase [3].
The theoretical advantage of bi-level CPAP could be the
prevention of alveolar collapse through a swing betweenal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(ΔP) created by this mechanism could generate a tidal
volume responsible for a decrease in the work of
breathing [4].
However only few studies were performed on newborns
and they were mainly focused on term babies with central
hypoventilation syndrome [5].
To date there are few published data on the effects of
bi-level CPAP in preterm infants and no data on the
hemodynamic changes related to the use of this respira-
tory support. Nevertheless, it has been demonstrated
that the application of an end-expiratory positive pressure
(PEEP) can interfere with venous return and cardiac
output [6].
The present study aims to evaluate the hemodynamic
effects on cardiac outputs and venous return of bi-level




A prospective study was conducted in a cohort of VLBWIs
admitted at birth to the Neonatal Intensive Care Unit
(NICU) of Bologna University Hospital (Italy) between
January 2012 and May 2012. Infants were eligible for in-
clusion in the study if they developed signs of RDS requir-
ing nCPAP support within the first 24–72 hours of life.
RDS was defined in presence of clinical features of respira-
tory distress (tachypnea, grunting, chest retractions, nasal
flaring), need of continuous positive pressure to maintain
oxygen saturation > 85% and compatible radiological
findings (e.g. reticulo-granular pattern, ground glass
appearance, air bronchograms, reduced lung volume).
In order to be included in the study, infants should
have been hemodynamically stable (normal blood pressure,
normal urine output and no need for inotropes).
Infants with congenital heart disease, congenital mal-
formations or assisted with mechanical ventilation were
excluded.
Each patient was supported with n-CPAP for several
hours, and switched to bi-level CPAP for a study period of
an hour. At the end of the study period all the subjects
were put back on n-CPAP.
The Infant Flow® SiPAP system (Viasys Healthcare,
Yorba Linda, CA, USA), which allows the operator to
switch from n-CPAP to bi-level CPAP mode without
interruption of the respiratory support or changes of
the device circuit, was used for the present study. Short
bi-nasal prongs of the largest size fitting comfortably
the patient’s nares were used in order to minimize air
leaks. Alternatively, nasal masks of the appropriate size
for the patient’s nose were used.
Nasal CPAP was set at 4–5 cm H20 and bi-level CPAP
as follows: Phigh 8 cm H2O, Plow 4-5cmH2O, Thigh0.5-0.6 seconds, rate 20 breaths/min. The minimal frac-
tional inspired oxygen saturation (FiO2) was set in order
to maintain oxygen saturation (SpO2), monitored through
a transcutaneous device, between 85 and 94%. Before and
after the study period, blood pressure was recorded, a ca-
pillary blood gas analysis was collected to detect the PCO2
level, and an echocardiographic study was performed to
evaluate the hemodynamic parameters.
Blood pressure was measured non-invasively by the
oscillometric method. Three values of mean blood pres-
sure were averaged and compared with normal values for
gestational age.
Hemodynamic measurements
The echocardiographic study was performed using a Philips
HD11 XE (Philips Ultrasound, Andover, MA, USA) ultra-
sound system with a 12-4 Hz transducer incorporating
colour flow and pulse wave Doppler. No angle correction
was used. Left ventricular output (LVO), right ventricular
output (RVO), superior vena cava (SVC) flow, the diameter
and the characteristics of the ductus arteriosus (DA) and
foramen ovale were evaluated. RVO, LVO and SVC flow
were measured according to previously published
methodology [7,8]. For the calculation of flow, the fol-
lowing formula was used: flow = (velocity time integral ×
(π × (diameter2⁄4) × heart rate)⁄body weight. Six or more
cycles were averaged for these measurements. Cardiac
outputs <150/kg/min and SVC flow <40 ml/kg/min were
considered as low blood flows [7,8]. Ductal diameter was
determined from a 2D image, using a high parasternal
position in a way that the whole length of the duct could
be visualized. The diameter was taken at the smallest
point at the pulmonary side of the duct. Maximum LR
flow velocity (Vmax), flow pattern (continuous, pulsatile)
and % of RL shunt were also recorded [9]. The McNamara
echocardiographic criteria were used to define an
hemodynamically significant duct [10]. The presence
of a patent foramen ovale was also assessed and a
diameter >3 mm was considered hemodynamically sig-
nificant. For each patient, all echocardiographic measure-
ments were taken by a single operator. All the images
were saved on magnetic optical disks. The EchoPAC
software (GE Vingmed Ultrasound EchoPAC 7.00, Horten,
Norway) was used for off-line analysis performed by a
second investigator blinded to the respiratory support
method. Ethics approval and written informed consent
were obtained from each patient parent/guardian. The
study protocol was approved by the Institutional Ethics
Committee of S.Orsola-Malpighi Hospital, Bologna.
Statistics
Statistical analysis was performed using SPSS 13.0 for
Windows (Statistical Package for Social Sciences, SPSS
Inc, Chicago, Ill, US).
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power of the study and a type II error probability. Based
on previous studies in literature [11] we estimated that a
sample size of 16 patients was sufficient to observe a 25%
reduction of both cardiac outputs (power = 0.8, α = 0.05,
one tail).
Comparison of echocardiographic measurements be-
tween n-CPAP and bi-level CPAP was performed using
Wilcoxon signed rank test. Spearman test was used to
correlate RVO and LVO with SVC flow. Results were
expressed as mean ± standard deviation if not specified
otherwise. P values <0.05 were considered statistically
significant.
Results
Thirty-two VLBWIs were admitted to the NICU during
the study period. Fourteen subjects (43.8%) were excluded
for the following reasons: 2 infants were on mechanical
ventilation, 6 without respiratory support or with nasal
cannulae, 2 infants had congenital heart disease and 4
were not enrolled because the investigator was unavailable
at the time of the study.
The demographic characteristics of the enrolled infants
are reported in Table 1.
The 18 subjects included in the study (8 males, 10
females) had a median gestational age (GA) of 30 weeks
(range 25–33 weeks) and a median birth weight (BW) of
1076 g (range 499–1490 g). All infants were assisted withTable 1 Demographic characteristics of the study population
Patients Sex GA (wks + days) BW(g)
1 M 33 + 3 1080
2 M 28 1230
3 F 25 + 6 934
4 M 30 1320
5 M 29 + 6 1147
6 F 32 + 2 1407
7 F 28 990
8 F 26 757
9 M 30 1322
10 F 33 + 4 1447
11 F 30 880
12 F 30 499
13 M 26 + 4 700
14 F 32 1076
15 M 33 1060
16 F 32 + 1 1490
17 M 27 + 5 1076
18 F 27 + 5 915
GA, gestational age; BW birth weight.n-CPAP because of respiratory distress; surfactant was
administered to 50% of the subjects prior the enrollment
in the present study. The subjects received surfactant either
on admission to the unit when intubated at birth in the de-
livery room, or within 4 hours from birth following the
InSurE (Intubation-Surfactant-Extubation) procedure when
not intubated at birth (age at the time of surfactant admin-
istration: 0–4 hours of life). For these subjects the study was
performed at least 12 hours after surfactant administration
(age at the time of the study: 18–65 hours of life).
Mean vascular diameters were: aorta 0.47 cm ±0.06,
pulmonary artery 0.5 cm ± 0.05, SVC 0.33 cm ± 0.07.
Fourteen newborns (77.8%) had a PDA at the time of the
study. Eight subjects met the echocardiographic criteria
for a moderate hemodynamically significant duct.
Echocardiographic measurements are reported in Table 2:
there were no significant changes of blood flow between
the two different methods of respiratory support. However,
a significant reduction of pCO2 values was observed after
the respiratory support with the bi-level CPAP (p = 0.01).
Four patients presented LVO values <150 ml/kg/min
both on nCPAP and bi-level CPAP; moreover, 2 patients
had a low LVO only on bi-level CPAP. No low RVO or
SVC flow was observed. No differences were also observed
when considering the hemodynamic characteristics of the
DA (Table 3).
Significant positive correlations between LVO and SVC



















Table 2 Comparison between hemodynamic parameters:
bi-level vs nasal CPAP (mean ± SD)
nCPAP Bilevel p
LVO (ml/kg/min) 222.17 ± 81.4 211.4 ± 75.3 .35
VTI (cm) 8.25 ± 2 7.93 ± 1.3 .42
SV (ml) 1.49 ± 0.6 1.41 ± 0.4 .35
RVO (ml/kg)min) 287.8 ± 96 283.4 ± 87.4 .71
VTI (cm) 10.17 ± 2.8 9.86 ± 1.8 .56
SV (ml) 1.97 ± 0.7 1.96 ± 0.6 .85
SVC (ml/kg/min) 135.38 ± 47.8 137.48 ± 46.6 .50
VTI (cm) 11.3 ± 3.2 11.87 ± 2.9 .35
HR (bpm) 146.88 ± 2.07 143.55 ± 1.56 .61
pCO2 (mm Hg) 47.96 ± 6.9 43.66 ± 4.5 .01
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between RVO and SVC flow was present when the pa-
tients where on n-CPAP (ρ = 0.73; p = 0.01) but not on
bi-level CPAP (ρ = 0.37; p = 0.14). When comparing the
characteristics of the subjects that showed an improve-
ment in central blood flows on bi-level CPAP with those
who showed a worsening no significant differences were
found in terms of BW and GA. Moreover, pCO2 variations
did not correlate with modifications of central blood flow
(LVO: ρ = 0.11, p = 0,657; RVO: ρ = −0.307, p = 0.216;
SVC: ρ = −0.13, p = 0.197).
Discussion
The present study shows that bi-level CPAP does not
affect central blood flow in preterm infants with RDS.
Current literature regarding the application of bi-level
CPAP to infants is scarce and mainly focused on its effi-
cacy as a non-invasive ventilation tool [4,12,13].
To date few papers were published on preterm new-
borns. One of these studies showed a significant gas
exchange improvement when the babies were assisted
with bi-level CPAP [10]. In a randomized controlled trial
(RCT) that compared the use of nasal versus bi-level
CPAP in infants with RDS, the subjects randomized in the
bi-level branch showed a better outcome in terms of days
of respiratory support and days of oxygen dependency [4].
The effectiveness of bi-level CPAP in the post-extubation
phase is controversial. The support with bi-level CPAP right
after the InSurE procedure seemed to reduce the chancesTable 3 Hemodynamic characteristics of the ductus
arteriosus (mean ± SD)
nCPAP Bilevel p
Ductus arteriosus
Pulsatile pattern (%) 57.1 57.1 n/a
Vmax (m/sec) 1.68 ± 0.5 1.46 ± 0.38 0.19
% R-L shunt 6.2 ± 10.6 12.6 ± 11.7 0.22of extubation failure and need of mechanical ventilation
[13]; however, a randomized trial published in 2012 showed
no differences in the rate of sustained extubation (>7 days)
between the subjects assisted with bi-level CPAP and
those with nasal CPAP [14].
A recent trial showed that nasal intermittent positive-
pressure ventilation (IPPV) is not superior to nasal CPAP
in terms of major outcomes such as death and broncho-
pulmonary dysplasia [15].
To our knowledge this is the first study that has evalu-
ated the safety of bi-level CPAP from the hemodynamic
point of view.
Interactions between respiratory and cardiovascular
systems are complex; in particular the application of an
end-expiratory positive pressure (PEEP) changes these in-
teractions so that on one hand oxygenation is improved
but on the other it can interfere with venous return and
therefore with cardiac output [16].
Animal model studies show that PEEP modifies the
shape of venous return curve by increasing the critical
pressure through a distortion of venous geometry, for
example at the entrance of the venae cavae into the
thorax. It is important to note that volemic status may
largely influence the effects of PEEP. In fact hypovolaemia
is likely to blunt the compensatory rise in systemic blood
pressure; conversely, volemic expansion can contrast the
effect of PEEP on venous return [6].
Theoretically there is potential for higher PEEP, as by
opening up the lungs, it may reduce pulmonary vascular
resistance and increase pulmonary and systemic blood
flow [11].
Several studies focused on the cardiovascular effects of
PEEP administration through invasive and non-invasive
mechanical ventilation. Nasal CPAP with a mean level of
4 cm H2O does not influence cardiac output in preterm
infants [17]; however a study on animal models showed
that increases of PEEP from 4 to 10 cm H2O led to a
significant decrease in the left pulmonary artery flow
and an increased right to left shunting through the
ductus arteriosus; the authors speculated this was likely
due to the concurrent increase in the pulmonary vas-
cular resistance and to a physical constraint (increasing
intrathoracic pressure) placed on the heart by the over-
expanded lung [18].
In a study on mechanically ventilated newborns, an in-
crease of PEEP from 5 to 8 cmH2O led to a RVO decrease
without causing either positive or negative relevant clinical
effects on systemic blood flow in the majority of the
infants [11]. However 36% of the subjects showed an
improvement in SVC flow presumably as a consequence of
improved lung compliance due to alveolar recruitment and
an optimised pulmonary volume. When PEEP is set too low,
blood will be shunted away from the collapsed alveoli pro-
ducing a regional increase in pulmonary vascular resistance.
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does not modify venous return and cardiac outputs.
In this study RVO and LVO mean values were consistent
with those reported in literature [7] while mean SVC values
resulted slightly higher [8]. This difference may be ascribed
to the higher complexity of SVC flow echocardiographic
measurement. Both SVC diameters and doppler velocities
resulted higher than the values reported in literature.
However, if any error was made in the assessment of the
SVC flow, it is unlikely that it could have altered the com-
parison between the two ventilation modalities because
the same operator performed both the echocardiographic
assessments of each patient. Overall 6 infants showed low
LVO without any clinical implication; in fact all the en-
rolled subjects remained stable (normal blood pressure,
normal urine output, no need for inotropes) during the
whole study period.
A recent study [19] performed on preterm newborns
in the first hour of life showed a LVO well below the
threshold of 150 ml/kg/min suggested by Evans et al. [7]
for the first 24 hours of life. The authors found a mean
LVO value of 71 ml/kg/min (range 61–110 at 1 hour of
life and ascribed this finding to the progressive physio-
logical improvement of cardiac function during the transi-
tional period [20]. This might explain our findings.
While cardiac outputs are greatly influenced by both
ductal and atrial shunting during the transitional period
[21,22] SVC flow is independent [20] resulting in a lack
of relationship between cardiac outputs and SVC flow
[21]. On the opposite, we found significant positive corre-
lations between outputs and SVC flow. Only the correl-
ation between RVO and SVC during bi-level CPAP
support resulted to be still positive but not statistically
significant.
We hypothesized that atrial and ductal shunting did
not represent a variable in our study. In fact the charac-
teristics of the ductus arteriosus (flow pattern, velocity
peak,% of left-to-right shunt) were similar during bi-level
and nasal NCPAP support. Moreover a significant ductal
shunt results in an increased LVO to RVO ratio due to a
relative increase of LVO [9], a finding that we did not
observe in our study.
We found a significant decrease in pCO2 during bi-level
CPAP support that was not related to central blood flow
variations and thus not to be ascribed to a change in the
pulmonary perfusion. It’s likely that bi-level CPAP, by cyc-
lic variations of PEEP, may improve alveolar recruitment
and optimize ventilation resulting in a decrease of pCO2
as described by previous studies [12]. However because
the decrease in pCO2 is not clinically relevant (47.96 ± 6.9
vs 43.66 ± 4.5 mmHg) we would not speculate further.
The demographic characteristics of our population were
analysed in order to detect differences between the sub-
jects who decreased central blood flow during bi-levelCPAP support and those who didn’t and no differences
were found in terms of GA and BW.
Therefore on the basis of these findings it is not pos-
sible to identify a group of subjects that may specifically
benefit from one of the two ventilatory support.
A paper published in 2009 [4] found that bi-level
CPAP, when used as a first choice treatment for RDS in
preterm babies, induced the same changes of nasal CPAP
in the level pulmonary inflammatory cytokines.
The present study adds that bi-level CPAP is a safe
ventilatory choice not only in terms of pulmonary injury
but also from the hemodynamic point of view.
The main limitations of the study are the small number
of patients included and the selective inclusion criteria.
The sample size was adequate to observe clinically
relevant changes in blood flow; however it’s not sufficient
to exclude flow changes less than 25%. Such small changes
in central blood flow may not have clinical implications.
In our study the application of bi-level CPAP resulted in
small changes (sometimes improvement, sometimes wors-
ening) of central blood flow and this is probably why
changes in the clinical conditions of the patients were not
observed.
Moreover echocardiography is a technique with many
weaknesses: measurement errors, poor image quality due
to a limited acoustic access in some patients, artefacts. All
these limitations play an important role and should be
taken into account especially when the number of the pa-
tients is small such as in the present study.
Lastly, we included in the study only stable infants
without cardiovascular compromise and therefore our
results may not be extended to critical infants.
In a recent paper, published by Becker et al [23]. the
authors measured central blood flow during respiratory
support different levels of CPAP (4, 6 and 8 cmH2O) in
a population of preterms with minimal lung disease.
They hypothesized that stable infants (without inotropic
support) may be able to compensate for the increased
intrathoracic pressure caused by CPAP, that is, they may
have had an initial decrease in cardiac output but they
might have compensated rapidly with a transient increase
in heart rate and subsequent recovery of cardiac output.
This may also apply to our findings since the populations
and the pressure levels were similar even though we used a
different respiratory device. Therefore our results should be
interpreted with caution as they may not apply to infants
with cardiovascular instability. Other studies should be car-
ried out to confirm our findings in critically ill infants.
Competing interests
All the authors declare that they have no conflict of interest with this paper.
Authors’ contributions
GA, SG and GF designed the study. GA performed ECHO scan. FV performed
the offline analysis. AA performed statistical analysis. GA and AA wrote the
Aquilano et al. Italian Journal of Pediatrics 2014, 40:60 Page 6 of 6
http://www.ijponline.net/content/40/1/60first draft of the paper, which was revised by all the other authors of the
paper. All authors read and approved the final manuscript.
Received: 4 February 2014 Accepted: 11 June 2014
Published: 21 June 2014References
1. Antonescu-Turcu A, Parthasarathy S: CPAP and bi-level PAP therapy: new
and established roles. Respir Care 2010, 55(9):1216–1229.
2. Verder H: Nasal CPAP has become an indispensable part of the primary
treatment of newborns with respiratory distress syndrome. Acta Pediatr
2007, 96(4):272–276.
3. DiBlasi: CPAP for respiratory care of the newborn infant. Respir Care 2009,
54(9):1209–1235.
4. Lista G, Castoldi F, Fontana P, Daniele I, Caviglioli F, Rossi S, Mancuso D,
Reali R: Nasal continuous positive airway pressure (CPAP) versus bi-level
nasal CPAP in preterm babies with respiratory distress syndrome: a
randomised control trial. Arch Dis Child Fetal Neonatal Ed 2010, 95:F85–F89.
5. Tibballs J, Henning RD: Non invasive ventilation strategies in the
management of a newborn infant and three children with congenital
central hypoventilation syndrome. Pediatr Pulmonol 2003, 36:544–548.
6. Feihl F, Broccard AF: Interaction between respiration and systemic
hemodynamics. Part I: basic concepts. Intensive Care Med 2009, 35:45–54.
7. Evans N, Kluckow M: Early determinants of right and left ventricular
output in ventilated preterm infants. Arch Dis Child 1996, 74:F88–F94.
8. Kluckow M, Evans N: Superior vena cava flow in newborn infants: a novel
marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed 2000,
82:F182–F187.
9. De Waal K: The methodology of doppler derived central blood flow
measurement in newborn infants. Int J Pediatr 2012, 2012:680162.
10. McNamara PJ, Sehgal A: Towards rational management of the patent
ductus arteriosus: the need for disease staging. Arch Dis Child Fetal
Neonatal Ed 2007, 92(6):F424–F427.
11. De Waal K, Evans N, Osborn DA, Kluckow M: Cardiorespiratory effects of
changes in end expiratory pressure in ventilated newborns. Arch Dis
Child Fetal Neonatal Ed 2007, 92:F444–F448.
12. Migliori C, Motta M, Angeli A, Chirico G: Nasal bilevel vs Continuous
Positive Airway Pressure in Preterm infants. Pediatr Pulmonol 2005,
40:426–430.
13. Ancora G, Maranella E, Grandi S, Pierantoni L, Guglielmi M, Faldella G: Role
of bilevel positive airway pressure in the management of preterm
newborns who have received surfactant. Acta Pediatr 2010, 99:1807–1811.
14. O’Brien K, Campbell C, Brown L, Wenger L, Shah V: Infant flow biphasic
nasal continuous positive airway pressure (BP- NCPAP) vs. infant flow
NCPAP for the facilitation of extubation in infants ≤ 1,250 grams: a
randomized controlled trial. BMC Pediatr 2012, 12:43.
15. Kirpalani H, Millar D, Lemyre B, Yoder BA, Chiu A, Roberts RS: A Trial
Comparing Noninvasive Ventilation Strategies in Preterm Infants. N Engl
J Med 2013, 369:611–620.
16. Abdel-Hady H, Matter M, Hammad A, El-Refaay A, Aly H: Hemodynamic
changes during weaning from nasal continuous positive airway pressure.
Pediatrics 2008, 122(5):e1086-90.
17. Moritz B, Fritz M, Mann C, Simma B: Nasal conti does not change cardiac
output in preterm infants. Am J Perinatol 2008, 25:105–110.
18. Polglase GR, Hooper SB, Gill AW, Allison BJ, McLean CJ, Nitsos I, Pillon JJ,
Kluckow M: Cardiovascular and pulmonary consequences of airway
recruitment in preterm lambs. J Appl Physiol 2009, 106:1347–1355.
19. Sehgal A, Mak W, Dunn E, Whyte H, McCrindle B, McNamara PJ:
Haemodynamic changes after delivery room surfactant administration to
very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2010,
95:F345–F351.
20. Kluckow M: Low systemic blood flow and pathophysiology of the
preterm transitional circulation. Early Hum Dev 2005, 81:429–437.
21. Miletin J, Dempsey EM: Low superior vena cava flow on day 1 and
adverse out come in the very low birthweight infant. Arch Dis Child Fetal
Neonatal Ed 2008, 93:F368–F371.22. Kluckow M, Evans N: Low systemic blood flow in the preterm infant.
Semin Neonatol 2001, 6:75–84.
23. Beker F, Rogerson SR, Hooper SB, Wong C, Davis PG: The effects of nasal
continuous positive airway pressure on cardiac function in premature
infants with minimal lung disease: a crossover randomized trial. J Peds
2014, 164:726–729.
doi:10.1186/1824-7288-40-60
Cite this article as: Aquilano et al.: Bi-level CPAP does not change
central blood flow in preterm infants with respiratory distress
syndrome. Italian Journal of Pediatrics 2014 40:60.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
